Moreover, hypoxia and HIF-1α in turn can promote the selection of LSCs in CML that are refractory to IM and bortezomib [90, 94, 133]. This evidence concerns the gene HIF1A and chronic myelogenous leukemia, BCR-ABL1 positive.